{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:36:13Z","timestamp":1789821373428,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009893","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T00:00:00Z","timestamp":1395878400000}}],"reference-count":70,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009893.pub2","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T13:29:36Z","timestamp":1395926976000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation"],"prefix":"10.1002","volume":"2016","author":[{"given":"Carlos A","family":"Salazar","sequence":"first","affiliation":[{"name":"Universidad Peruana Cayetano Heredia; Department of Medicine; Avenida Honorio Delgado 430 San Martin de Porres Lima Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"del Aguila","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia; Department of Medicine; Avenida Honorio Delgado 430 San Martin de Porres Lima Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika G","family":"Cordova","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia; Department of Medicine; Avenida Honorio Delgado 430 San Martin de Porres Lima Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,27]]},"reference":[{"issue":"23","key":"10.1002\/14651858.CD009893.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehp318","article-title":"Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomised dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists","volume":"30","author":"Lip","year":"2009","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0002|cit2","unstructured":"NCT01136408 Open label, randomised exploratory dose response study in pharmacodynamics and safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 weeks in patients with non-valvular atrial fibrillation in comparison to warfarin http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01136408 accessed 2007 (reported)"},{"issue":"3","key":"10.1002\/14651858.CD009893.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1160\/TH09-07-0509","article-title":"Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation","volume":"103","author":"Olsson","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"issue":"9","key":"10.1002\/14651858.CD009893.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD009893.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD009893.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0007|cit7","unstructured":"FDA Advisory Committee Dabigatran briefing document [Boehringer Ingelheim] http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm226009.pdf (accessed 4th March 2014) 2010 1 168"},{"issue":"9","key":"10.1002\/14651858.CD009893.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0735-1097(03)00255-9","article-title":"Ximalagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation","volume":"41","author":"Petersen","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"9397","key":"10.1002\/14651858.CD009893.pub2-BIB0009|cit9","first-page":"1691","article-title":"Stroke\u00a0prevention\u00a0with the\u00a0oral\u00a0direct\u00a0thrombin\u00a0inhibitor\u00a0ximelagatran\u00a0compared\u00a0with\u00a0warfarin\u00a0in\u00a0patients\u00a0with\u00a0non-valvular\u00a0atrial\u00a0fibrillation\u00a0(SPORTIF\u00a0III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD009893.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"issue":"9526","key":"10.1002\/14651858.CD009893.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"issue":"9609","key":"10.1002\/14651858.CD009893.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","author":"Bousser","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD009893.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009893.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"Eriksson","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"13","key":"10.1002\/14651858.CD009893.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009893.pub2-BIB0016|cit16","first-page":"633","article-title":"Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation","volume":"104","author":"Weitz","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"issue":"9591","key":"10.1002\/14651858.CD009893.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"issue":"9386","key":"10.1002\/14651858.CD009893.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Connolly SJ \u00a0Eikelboom J \u00a0Dorian P \u00a0Hohnloser SH \u00a0Gretler DD \u00a0Sinha U \u00a0et al Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomised, dose-ranging study (Explore-Xa) European Heart Journal 2013 1498 505","DOI":"10.1093\/eurheartj\/eht039"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0020|cit20","unstructured":"NCT00152971 Dabigatran etexilate vs enoxaparin in prevention of venous thromboembolism (VTE) post total knee replacement http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00152971?term=Dabigatran+etexilate+vs+enoxaparin+in+prevention+of+venous+thromboembolism+%28VTE%29+post+total+knee+replacement&rank=1 (accessed September 2013)"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0021|cit21","unstructured":"NCT00246025 A study of BIBR 1048 in prevention of venous thromboembolism in patients with TKR surgery http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00246025?term=A+study+of+BIBR+1048+in+prevention+of+venous+thromboembolism+in+patients+with+TKR+surgery&rank=1 (accessed September 2013)"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0022|cit22","unstructured":"NCT00680186 Phase III study testing efficacy and safety of oral dabigatran etexilate vs warfarin for 6 months. Treatment for acute symptomatic venous thromboembolism (VTE) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00680186?term=oral+dabigatran+etexilate+vs+warfarin&rank=1 (accessed September 2013)"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0023|cit23","unstructured":"NCT00904800 AZD0837 Extended Release (ER) Japan Study http:\/\/clinicaltrials.gov\/show\/NCT00904800 (accessed September 2013)"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0024|cit24","unstructured":"NCT01225822 BIBR 1048 dose range finding study in prevention of venous thromboembolism in patients with primary elective total hip or knee replacement surgery http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01225822 (accessed September 2013)"},{"issue":"6","key":"10.1002\/14651858.CD009893.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","article-title":"A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomised, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)","volume":"163","author":"Werf","year":"2012","journal-title":"Americal Heart Journal"},{"issue":"24","key":"10.1002\/14651858.CD009893.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1002\/14651858.CD009893.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomised, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0028|cit28","unstructured":"Connolly SJ Randomised comparison of the effects of two doses of dabigatran etexilate on clinical outcomes over 4.3 years: results of the RELY-ABLE double-blind randomised trial http:\/\/www.abstractsonline.com\/plan\/ViewAbstract.aspx?mID=2974&sKey=94d74361-5616-4a16-8a8e-a3739885329a&cKey=770e5366-02c1-4314-9a37-76ab178d193b&mKey=14145d5b-f96b-4354-8237-8f0937744ba4 [American Heart Association Scientific Sessions]"},{"issue":"11","key":"10.1002\/14651858.CD009893.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomised trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD009893.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial","volume":"105","author":"Eriksson","year":"2011","journal-title":"Thrombosis and Haemostasis"},{"issue":"10","key":"10.1002\/14651858.CD009893.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009893.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0033|cit33","unstructured":"AstraZeneca Long-term treatment with the oral direct thrombin inhibitor H 376\/95, compared to warfarin, as stroke prophylaxis in patients with atrial fibrillation. An open 10-year follow-up study. Final report at 7 years (Supplement to 5-year interim analysis report) AstraZeneca Synopsis"},{"issue":"9","key":"10.1002\/14651858.CD009893.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4244\/EIJV8I9A162","article-title":"A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients","volume":"8","author":"Vranckx","year":"2013","journal-title":"EuroIntervention"},{"issue":"5","key":"10.1002\/14651858.CD009893.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jacc.2006.06.004","article-title":"Trials and tribulations of non-inferiority: the ximelagatran experience","volume":"48","author":"Albers","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD009893.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1592\/phco.28.11.1354","article-title":"Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases","volume":"28","author":"Baetz","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD009893.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"244","DOI":"10.18553\/jmcp.2009.15.3.244","article-title":"Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States","volume":"15","author":"Baker","year":"2009","journal-title":"Journal of Managed Care Pharmacy"},{"issue":"19","key":"10.1002\/14651858.CD009893.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options - why the FDA approved a higher but not a lower\u00a0 dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009893.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD009893.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1532-5415.2010.02767.x","article-title":"Competing risk of death: an important consideration in studies of older adults","volume":"58","author":"Berry","year":"2010","journal-title":"Journal of the American Geriatric Society"},{"issue":"5","key":"10.1002\/14651858.CD009893.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cct.2006.04.005","article-title":"The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee","volume":"27","author":"Boudes","year":"2006","journal-title":"Contempory Clinical Trials"},{"issue":"21","key":"10.1002\/14651858.CD009893.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1093\/eurheartj\/ehp384","article-title":"The RE-LY study: Randomised Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin","volume":"30","author":"Camm","year":"2009","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD009893.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ijcard.2012.03.148","article-title":"Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients","volume":"167","author":"Capodanno","year":"2012","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0044|cit44","unstructured":"European Medicines Agency Press release: Astra Zeneca withdraws its application for ximelagatran 36-mg film-coated tablets http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/02\/WC500074073.pdf"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-pharmtox-010611-134633","article-title":"Old versus new oral anticoagulants: focus on pharmacology","volume":"52","author":"Fareed","year":"2012","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"2","key":"10.1002\/14651858.CD009893.pub2-BIB0046|cit46","first-page":"111","article-title":"Atrial fibrillation and cardioembolic stroke","volume":"52","author":"Ferro","year":"2004","journal-title":"Minerva Cardioangiologica"},{"issue":"7","key":"10.1002\/14651858.CD009893.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.amjcard.2004.06.023","article-title":"Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study)","volume":"94","author":"Friberg","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"20","key":"10.1002\/14651858.CD009893.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1053\/euhj.2000.2300","article-title":"Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications","volume":"22","author":"Frykman","year":"2001","journal-title":"European Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD009893.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1161\/CIRCULATIONAHA.106.177292","article-title":"ACC\/AHA\/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines: developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"issue":"16","key":"10.1002\/14651858.CD009893.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2287-92","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin","volume":"110","author":"Gage","year":"2004","journal-title":"Circulation"},{"issue":"20","key":"10.1002\/14651858.CD009893.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomised trials translate into clinical practice?","volume":"290","author":"Go","year":"2003","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD009893.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD009893.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009893.pub2-BIB0054|cit54","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD009893.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/hrt.2004.042465","article-title":"Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non valvar atrial fibrillation: a record linkage study in a large British population","volume":"91","author":"Jones","year":"2005","journal-title":"Heart"},{"issue":"5","key":"10.1002\/14651858.CD009893.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/jnnp.2004.048827","article-title":"Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischemic stroke","volume":"76","author":"Kimura","year":"2005","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"22","key":"10.1002\/14651858.CD009893.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1093\/eurheartj\/ehm358","article-title":"Outcome parameters for trials in atrial fibrillation: executive summary","volume":"28","author":"Kirchhof","year":"2007","journal-title":"European Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD009893.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation","volume":"60","author":"Lip","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD009893.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD009893.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-155-10-201111150-00004","article-title":"Risk for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial","volume":"155","author":"Oldgren","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009893.pub2-BIB0061|cit61","first-page":"479","article-title":"New trends in anticoagulant therapy","volume":"6","author":"Pengo","year":"2004","journal-title":"Israel Medical Association Journal"},{"issue":"10","key":"10.1002\/14651858.CD009893.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1538-7836.2008.03075.x","article-title":"Warfarin for atrial fibrillation in community-based practice","volume":"6","author":"Rose","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD009893.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/oxfordjournals.aje.a115199","article-title":"Competing risks bias arising from an omitted risk factor","volume":"129","author":"Schatzkin","year":"1989","journal-title":"American Journal of Epidemiology"},{"issue":"13","key":"10.1002\/14651858.CD009893.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"E672","DOI":"10.1016\/S0735-1097(12)60673-1","article-title":"Bleeding as important as ischemic stroke in predicting mortality in atrial fibrillation","volume":"59","author":"Sharma","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD009893.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD009893.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11739-009-0314-8","article-title":"New direct thrombin inhibitors","volume":"4","author":"Squizzato","year":"2009","journal-title":"Internal and Emergency Medicine"},{"issue":"5","key":"10.1002\/14651858.CD009893.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events. Meta-analysis of non-inferiority randomised control trial","volume":"172","author":"Uchino","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009893.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00129784-200303030-00006","article-title":"New anticoagulants: current status and future potential","volume":"3","author":"Weitz","year":"2003","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"9","key":"10.1002\/14651858.CD009893.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly; the Framingham Heart Study","volume":"147","author":"Wolf","year":"1987","journal-title":"Archives of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009893.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009893","article-title":"Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with non-valvular atrial fibrillation","author":"Salazar","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009893.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T08:37:40Z","timestamp":1690274260000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009893.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Stroke Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,27]]},"references-count":70,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009893.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,27]]}}}